Test down-to-earth
Context:
- AstraZeneca, the company that makes the Covishield vaccine for Covid-19 pandemic, has admitted the inoculation has potential side effects.
- The company's admission, presented in a legal document before the High Court of Justice in London, conveys that the Covid vaccine can in extremely rare cases induce Thrombosis with Thrombocytopenia Syndrome (TTS).
What is Covishield?
- The Oxford-AstraZeneca Covid vaccine, sold as Covishield in India and Vaxzevria in Europe is a viral vector vaccine.
- It is adenovirus vector vaccine, a chimpanzee adenovirus - ChAdOx1 - has been modified to enable it to carry the Covid-19 (SARS-CoV-2) spike protein injected into the muscles of humans.
- It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic.
• Over 1.7 billion doses of Covishield have been administered so far globally.
• More than 175 crore doses of Covishield have been administered in India.
Column-1 | Column-2 |
|
|
It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic. | 1 |
12 | It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic. |
It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic. It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic. |
3 |
It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic. |
It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic. |
|
fdgfh |
fdgffgh |
paragraph
It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic. | It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic. |
It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic.
|
- It was manufactured and marketed in India in partnership with Punebased Serum Institute of India, and was widely used during the country’s fight against the deadly Covid-19 pandemic.
• Over 1.7 billion doses of Covishield have been administered so far globally.
• More than 175 crore doses of Covishield have been administered in India.